Olema Pharmaceuticals, Inc.
(NASDAQ : OLMA)

( )
OLMA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.25%39.900.9%$1278.55m
JNJJohnson & Johnson -0.04%170.120.7%$1252.92m
MRKMerck & Co., Inc. 0.33%78.480.7%$929.96m
ABBVAbbVie, Inc. 0.61%117.231.9%$725.42m
BMYBristol-Myers Squibb Co. -0.06%64.841.0%$719.56m
LLYEli Lilly & Co. 0.10%196.401.1%$573.53m
AZNAstraZeneca Plc 0.36%55.411.2%$533.60m
BTXBrooklyn ImmunoTherapeutics, Inc. -1.34%21.4012.8%$252.76m
GSKGlaxoSmithKline Plc 0.08%39.120.2%$191.58m
NVSNovartis AG -0.14%88.880.2%$173.40m
VTRSViatris, Inc. -0.94%15.850.0%$166.85m
CVACCureVac NV 2.51%112.750.0%$163.76m
NVONovo Nordisk A/S 0.90%79.820.1%$72.84m
SNYSanofi 0.23%52.860.2%$71.93m
ATNXAthenex, Inc. -1.18%5.020.0%$61.96m

Company Profile

Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.